The Anti-ictogenic Effects of Levetiracetam Are Mirrored by Interictal Spiking and High-frequency Oscillation Changes in a Model of Temporal Lobe Epilepsy

Overview

Journal Seizure

Publisher Elsevier

Specialty Neurology

Date 2015 Feb 4

PMID 25645630

Citations 14

Authors

Maxime Levesque

Charles Behr

Massimo Avoli

Affiliations

Soon will be listed here.

Abstract

Purpose: Mesial temporal lobe epilepsy (MTLE) is the most prevalent type of partial epileptic disorders. In this study, we have analyzed the impact of levetiracetam (LEV) in the pilocarpine model of MTLE.

Methods: Sprague-Dawley rats (n=19) were injected with pilocarpine (380 mg/kg, i.p.) to induce a status epilepticus. Twelve animals were used as controls and seven were treated with LEV. They were implanted with bipolar electrodes in the CA3 subfield of the hippocampus, entorhinal cortex (EC), dentate gyrus (DG) and subiculum and EEG-video monitored continuously from day 4 to day 14 after SE.

Results: Only 29% of LEV-treated animals had seizures compared to all controls following a latent period that was similar in duration. Seizure rates were lower in LEV-treated animals. In LEV-treated animals without seizures, lower interictal spike rates were found in all regions compared to controls. Analysis of interictal high-frequency oscillations (HFO s) revealed that LEV-treated animals without seizures had lower rates of interictal spikes with ripples (80-200 Hz) in CA3, EC and subiculum (p<0.01), whereas rates of interictal spikes with fast ripples (250-500 Hz) were significantly lower in CA3 and subiculum, compared to controls.

Conclusion: Our findings indicate that the anti-ictogenic properties of LEV are mirrored by decreases of interictal spike rate in temporal lobe regions, and are accompanied by subregion-specific decreases of HFO occurrence in CA3 and subiculum. Overall, this evidence suggest that LEV may inhibit neural network activity in regions that are known to play important roles in MTLE.

Citing Articles

High-frequency oscillations in epileptic and non-epileptic Alzheimer's disease patients and the differential effect of levetiracetam on the oscillations.

Shandilya M, Addo-Osafo K, Ranasinghe K, Shamas M, Staba R, Nagarajan S Brain Commun. 2025; 7(1):fcaf041.

PMID: 39949405 PMC: 11822293. DOI: 10.1093/braincomms/fcaf041.

The appearance of scalp high-frequency oscillations is associated with poor seizure control in pediatric epilepsy patients.

Maeda K, Hosoda N, Tsuboi H, Naito H, Kudo C, Fukumoto J Epilepsia Open. 2024; 10(1):107-119.

PMID: 39628036 PMC: 11803266. DOI: 10.1002/epi4.13032.

Brivaracetam and Levetiracetam Suppress Astroglial L-Glutamate Release through Hemichannel via Inhibition of Synaptic Vesicle Protein.

Fukuyama K, Okada M Int J Mol Sci. 2022; 23(9).

PMID: 35562864 PMC: 9101419. DOI: 10.3390/ijms23094473.

Levetiracetam Mechanisms of Action: From Molecules to Systems.

Contreras-Garcia I, Cardenas-Rodriguez N, Romo-Mancillas A, Bandala C, Zamudio S, Gomez-Manzo S Pharmaceuticals (Basel). 2022; 15(4).

PMID: 35455472 PMC: 9030752. DOI: 10.3390/ph15040475.

High-Frequency Oscillations and Epileptogenic Network.

Li X, Zhang H, Lai H, Wang J, Wang W, Yang X Curr Neuropharmacol. 2021; 20(9):1687-1703.

PMID: 34503414 PMC: 9881061. DOI: 10.2174/1570159X19666210908165641.

References

Loscher W, Honack D, Rundfeldt C . Antiepileptogenic effects of the novel anticonvulsant levetiracetam (ucb L059) in the kindling model of temporal lobe epilepsy. J Pharmacol Exp Ther. 1998; 284(2):474-9. View

Jacobs J, Zijlmans M, Zelmann R, Chatillon C, Hall J, Olivier A . High-frequency electroencephalographic oscillations correlate with outcome of epilepsy surgery. Ann Neurol. 2010; 67(2):209-20. PMC: 3769290. DOI: 10.1002/ana.21847. View

Lyseng-Williamson K . Levetiracetam: a review of its use in epilepsy. Drugs. 2011; 71(4):489-514. DOI: 10.2165/11204490-000000000-00000. View

Sugaya Y, Maru E, Kudo K, Shibasaki T, Kato N . Levetiracetam suppresses development of spontaneous EEG seizures and aberrant neurogenesis following kainate-induced status epilepticus. Brain Res. 2010; 1352:187-99. DOI: 10.1016/j.brainres.2010.06.061. View

Margineanu D, Matagne A, Kaminski R, Klitgaard H . Effects of chronic treatment with levetiracetam on hippocampal field responses after pilocarpine-induced status epilepticus in rats. Brain Res Bull. 2008; 77(5):282-5. DOI: 10.1016/j.brainresbull.2008.07.006. View

Mantegazza M, Curia G, Biagini G, Ragsdale D, Avoli M . Voltage-gated sodium channels as therapeutic targets in epilepsy and other neurological disorders. Lancet Neurol. 2010; 9(4):413-24. DOI: 10.1016/S1474-4422(10)70059-4. View

Doheny H, Whittington M, Jefferys J, Patsalos P . A comparison of the efficacy of carbamazepine and the novel anti-epileptic drug levetiracetam in the tetanus toxin model of focal complex partial epilepsy. Br J Pharmacol. 2002; 135(6):1425-34. PMC: 1573268. DOI: 10.1038/sj.bjp.0704606. View

Ben-Ari Y, Tremblay E, Ottersen O, Meldrum B . The role of epileptic activity in hippocampal and "remote" cerebral lesions induced by kainic acid. Brain Res. 1980; 191(1):79-97. DOI: 10.1016/0006-8993(80)90316-9. View

Huberfeld G, de la Prida L, Pallud J, Cohen I, Le Van Quyen M, Adam C . Glutamatergic pre-ictal discharges emerge at the transition to seizure in human epilepsy. Nat Neurosci. 2011; 14(5):627-34. DOI: 10.1038/nn.2790. View

10.

Klitgaard H, Matagne A, Grimee R, Vanneste-Goemaere J, Margineanu D . Electrophysiological, neurochemical and regional effects of levetiracetam in the rat pilocarpine model of temporal lobe epilepsy. Seizure. 2003; 12(2):92-100. DOI: 10.1016/s1059131102001930. View

11.

Stodieck S, Steinhoff B, Kolmsee S, Van Rijckevorsel K . Effect of levetiracetam in patients with epilepsy and interictal epileptiform discharges. Seizure. 2002; 10(8):583-7. DOI: 10.1053/seiz.2001.0582. View

12.

Levesque M, Bortel A, Gotman J, Avoli M . High-frequency (80-500 Hz) oscillations and epileptogenesis in temporal lobe epilepsy. Neurobiol Dis. 2011; 42(3):231-41. PMC: 4873283. DOI: 10.1016/j.nbd.2011.01.007. View

13.

Bagshaw A, Jacobs J, Levan P, Dubeau F, Gotman J . Effect of sleep stage on interictal high-frequency oscillations recorded from depth macroelectrodes in patients with focal epilepsy. Epilepsia. 2008; 50(4):617-28. PMC: 3792080. DOI: 10.1111/j.1528-1167.2008.01784.x. View

14.

Staba R, Wilson C, Bragin A, Fried I, Engel Jr J . Quantitative analysis of high-frequency oscillations (80-500 Hz) recorded in human epileptic hippocampus and entorhinal cortex. J Neurophysiol. 2002; 88(4):1743-52. DOI: 10.1152/jn.2002.88.4.1743. View

15.

Jacobs J, Levan P, Chander R, Hall J, Dubeau F, Gotman J . Interictal high-frequency oscillations (80-500 Hz) are an indicator of seizure onset areas independent of spikes in the human epileptic brain. Epilepsia. 2008; 49(11):1893-907. PMC: 3792077. DOI: 10.1111/j.1528-1167.2008.01656.x. View

16.

Levesque M, Salami P, Gotman J, Avoli M . Two seizure-onset types reveal specific patterns of high-frequency oscillations in a model of temporal lobe epilepsy. J Neurosci. 2012; 32(38):13264-72. PMC: 4878898. DOI: 10.1523/JNEUROSCI.5086-11.2012. View

17.

Racine R . Modification of seizure activity by electrical stimulation. II. Motor seizure. Electroencephalogr Clin Neurophysiol. 1972; 32(3):281-94. DOI: 10.1016/0013-4694(72)90177-0. View

18.

Haegelen C, Perucca P, Chatillon C, Andrade-Valenca L, Zelmann R, Jacobs J . High-frequency oscillations, extent of surgical resection, and surgical outcome in drug-resistant focal epilepsy. Epilepsia. 2013; 54(5):848-57. PMC: 3712982. DOI: 10.1111/epi.12075. View

19.

Vinogradova L, van Rijn C . Anticonvulsive and antiepileptogenic effects of levetiracetam in the audiogenic kindling model. Epilepsia. 2008; 49(7):1160-8. DOI: 10.1111/j.1528-1167.2008.01594.x. View

20.

Engel Jr J . Introduction to temporal lobe epilepsy. Epilepsy Res. 1996; 26(1):141-50. DOI: 10.1016/s0920-1211(96)00043-5. View